- Home
- MU vs SNY Comparison
MU vs SNY Comparison
Compare MU & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MU
- SNY
- Stock Information
- Founded
- MU 1978
- SNY 1994
- Country
- MU United States
- SNY France
- Employees
- MU N/A
- SNY N/A
- Industry
- MU Semiconductors
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- MU Technology
- SNY Health Care
- Exchange
- MU Nasdaq
- SNY Nasdaq
- Market Cap
- MU 135.3B
- SNY 116.5B
- IPO Year
- MU N/A
- SNY N/A
- Fundamental
- Price
- MU $124.53
- SNY $48.61
- Analyst Decision
- MU Strong Buy
- SNY Buy
- Analyst Count
- MU 27
- SNY 2
- Target Price
- MU $152.11
- SNY $62.50
- AVG Volume (30 Days)
- MU 24.9M
- SNY 2.2M
- Earning Date
- MU 06-25-2025
- SNY 07-31-2025
- Dividend Yield
- MU 0.37%
- SNY 3.29%
- EPS Growth
- MU N/A
- SNY 39.56
- EPS
- MU 5.50
- SNY 5.45
- Revenue
- MU $33,813,000,000.00
- SNY $48,817,552,946.00
- Revenue This Year
- MU $45.60
- SNY $3.39
- Revenue Next Year
- MU $25.78
- SNY $7.05
- P/E Ratio
- MU $22.64
- SNY $8.92
- Revenue Growth
- MU 58.22
- SNY N/A
- 52 Week Low
- MU $61.54
- SNY $45.80
- 52 Week High
- MU $136.43
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- MU 64.56
- SNY 46.26
- Support Level
- MU $121.28
- SNY $47.99
- Resistance Level
- MU $126.15
- SNY $49.43
- Average True Range (ATR)
- MU 3.69
- SNY 0.58
- MACD
- MU -1.12
- SNY 0.18
- Stochastic Oscillator
- MU 54.88
- SNY 56.15
About MU Micron Technology Inc.
Micron is one of the largest semiconductor companies in the world, specializing in memory and storage chips. Its primary revenue stream comes from dynamic random access memory, or DRAM, and it also has minority exposure to not-and or NAND, flash chips. Micron serves a global customer base, selling chips into data centers, mobile phones, consumer electronics, and industrial and automotive applications. The firm is vertically integrated.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.